Table 1. Baseline Demographics and Clinical Data of Study Patients.
| Characteristics | Patients (n = 70) |
|---|---|
| Sex (%) | |
| Male | 39 (55.7) |
| Female | 31 (44.3) |
| Age (mean ± SD, years) | 38–90 (63 ± 11.6) |
| Primary cancer (%) | |
| Pancreas cancer | 29 (41.4) |
| Gastric cancer | 21 (30.0) |
| Duodenal cancer | 6 (8.6) |
| Ampulla of Vater cancer | 2 (2.9) |
| Gallbladder cancer | 5 (7.1) |
| Bile duct cancer | 4 (5.7) |
| Other* | 3 (4.3) |
| Level of biliary obstruction (%) | |
| Upper common bile duct | 5 (7.1) |
| Lower common bile duct | 39 (55.7) |
| Whole common bile duct | 26 (37.1) |
| Type of biliary stent (%) | |
| Covered | 63 (90.0) |
| Uncovered | 7 (10.0) |
| Location of distal end of biliary stent (%) | |
| Beyond duodenal stent | 31 (44.3) |
| Within duodenal stent | 39 (55.7) |
| Location of duodenal obstruction† (%) | |
| Type I | 16 (22.9) |
| Type II | 49 (70.0) |
| Type III | 5 (7.1) |
| Timing of duodenal stenting (%) | |
| Before biliary stenting | 37 (52.9) |
| After biliary stenting | 33 (47.1) |
| Type of duodenal stent (%) | |
| Covered | 52 (74.3) |
| Uncovered | 18 (25.7) |
| Approach route for duodenal stenting (%) | |
| Fluoroscopically | 38 (54.3) |
| Endoscopically | 32 (45.7) |
*1 ovarian cancer, 1 lung cancer, 1 ureter cancer, †Type I, proximal to duodenal papilla without involvement of papilla; type II, at second part of duodenum with involvement of papilla; and type III, distal to papilla without involvement of papilla. SD = standard deviation